CRISPR‐Cas9 is the most advanced genome editing technology that is promising for treatment of disorders, particularly monogenic diseases. Gene editing system has been used for correcting several disease relevant mutations in mice through zygotic, somatic or ex vivo strategies. BioHeng is developing innovative CRISPR therapeutic tools with significantly improved efficiency and specificity. More information and progress will be released.
Copyright Nanjing Bioheng Biotech Co., Ltd.@ 2018 China All Rights Reserved